Relapsed and Resistant Pediatric Cancer

Unfortunately for many families, some cancers resist therapy, resulting in a situation where cancer cells do not die, continue growing or come back after initial response.

University of Michigan C.S. Mott Children’s Hospital is one of a very limited number of children’s cancer centers in the U.S. that offer certain experimental therapies to children, adolescents and young adults with recurrent illness (relapse), those whose disease has not responded to traditional treatment, and those with a diagnosis that has no reasonable cure. 

Clinical trials are extremely important for children with hard-to-treat or relapsed conditions. An oncology clinical trial tests new methods of treating pediatric cancers, such as new drug therapies, new approaches to surgery or radiation or new methods for biologically targeted therapy.   In a clinical trial, your child receives state of the art treatment and has a chance to be among the first to benefit from new therapies. 

Participating in a clinical trial also helps ensure that children diagnosed with cancer in the future will be benefit from what is learned from clinical trials today, just as your child benefits from what has been learned from past clinical trials.

C.S. Mott Children’s Hospital scientists are actively participating in the latest innovative treatment protocols and clinical trials in the nation to improve  survival rates and scientific understanding of childhood cancers. Our program offers access to Phase I clinical trials and First-in-children protocols available only at a very limited number of institutions. 

  • We are the only Children’s Oncology Group Phase I Consortium member in the state of Michigan, which means that we offer unique studies unavailable at other hospitals in Michigan.
  • We are one of the pioneers in offering high dose MIBG trials for relapsed or resistant neuroblastoma.
  • As one of only a handful of NANT (New Approaches to Neuroblastoma Therapy) and TACL (Therapeutic Advances in Childhood Leukemia) consortium member institution, we offer families access to a number of trials only available at NANT and TACL institutions.
  • Our oncologists offer new approaches in Precision Medicine through next generation gene sequencing in patients with relapsed, resistant and rare cancers.
  • Mott Children’s Hospital offers patients enrollment in U-M investigator-initiated protocols and studies unavailable at any other children’s medical center. 
  • Our team conducts Phase I, Phase Ib and Phase II trials sponsored by the National Cancer Institute and a number of pharmaceutical companies.  
  • All new patients are seen within 72 hours of being referred by their physician.

For more information about clinical trials available at C.S. Mott Children’s Hospital please contact our Cancer Answer Line at 1-800-865-1125 or by email.